Rapid generation of human recombinant monoclonal antibodies from antibody-secreting cells using ferrofluid-based technology.
CD138-ferrofluid
COVID-19
antibody secreting cells (ASCs)
antigen-specific ASCs
functional selection
human monoclonal antibodies
single cell PCR
transcriptionally active PCR (TAP)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
20
11
2023
accepted:
06
03
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
epublish
Résumé
Monoclonal antibodies (mAbs) are one of the most important classes of biologics with high therapeutic and diagnostic value, but traditional methods for mAbs generation, such as hybridoma screening and phage display, have limitations, including low efficiency and loss of natural chain pairing. To overcome these challenges, novel single B cell antibody technologies have emerged, but they also have limitations such as
Identifiants
pubmed: 38698845
doi: 10.3389/fimmu.2024.1341389
pmc: PMC11064063
doi:
Substances chimiques
Antibodies, Monoclonal
0
Recombinant Proteins
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1341389Informations de copyright
Copyright © 2024 Strazza, Rossi, Avati, Tiseo, Falcone, Cusi, Menichetti, Ricciardi-Castagnoli, Tinti and Pileri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.